Major Global Animal Health Company Collaborates with ZIVO Biosciences for Coccidiosis Study
BLOOMFIELD HILLS, Mich. ZIVO Bioscience, Inc. (NASDAQ: ZIVO), a leading biotech/agtech R&D company focused on developing therapeutic, medicinal, and nutritional products derived from proprietary algal cultures, has announced the commencement of a 42-day confirmatory study in partnership with a major global animal health company. This study aims to further validate the efficacy of ZIVO’s non-antibiotic, immune-modulating product for the treatment of coccidiosis in broiler chickens.
Coccidiosis is a highly contagious intestinal disease that affects poultry and other animals, causing significant economic losses for farmers and negatively impacting animal welfare. Conventional treatment options for coccidiosis often involve the use of antibiotics, which may raise concerns about antimicrobial resistance. ZIVO Bioscience’s innovative approach seeks to provide a safe and effective alternative to traditional treatments.
The new 42-day confirmatory study represents a significant milestone in ZIVO’s efforts to combat coccidiosis. By partnering with a major global animal health company, ZIVO aims to further validate the efficacy of its immune-modulating product in treating this prevalent disease. The study will assess the performance and health of broiler chickens over a 42-day period, evaluating factors such as weight gain, feed conversion ratio, lesion score, and oocyst count.
ZIVO Bioscience’s proprietary algal cultures have already shown promise in mitigating coccidiosis. The company’s product is designed to enhance the bird’s immune response against coccidiosis-causing parasites, reducing the need for antibiotic treatment and improving animal welfare. With this 42-day confirmatory study, ZIVO aims to gather additional data to strengthen the efficacy claims of its product.
This initiative comes at a time when ZIVO Bioscience is reporting positive financial performance compared to its competitors. In the first quarter of 2024, ZIVO reported a revenue increase of 0% year-on-year, while most of its competitors experienced a contraction in revenues by -9.33% during the same period. Despite the net loss recorded by ZIVO, it has managed to sustain its financial position better than its peers.
The collaboration with a major global animal health company not only demonstrates industry recognition of ZIVO Bioscience’s potential but also validates the significance of their research and development efforts. By partnering with established players in the animal health sector, ZIVO can leverage their expertise and resources to expedite the development and commercialization of its innovative products.
In conclusion, ZIVO Bioscience’s initiation of a 42-day confirmatory study for coccidiosis treatment in broiler chickens marks a significant milestone in their efforts to combat this prevalent disease. By collaborating with a major global animal health company, ZIVO aims to further validate the efficacy of its non-antibiotic, immune-modulating product. This study, coupled with ZIVO’s positive financial performance, highlights the company’s potential to revolutionize animal health and welfare in the poultry industry.
Comments